Assembly Biosciences Doses First Two Participants in Phase 2 Study of Oral NTCP Inhibitor ABI-6250 for Chronic Hepatitis Delta Virus
Key Highlights
- ➤ABI-6250 Phase 2 trial dosed first two participants with chronic HDV infection
- ➤Phase 2 study targets approximately 80 participants across two once-daily oral doses
- ➤Initial Phase 2 data expected in fourth quarter of 2027
- ➤Gilead can license ABI-6250 for a $90 million opt-in fee
- ➤ABI-6250’s four-day half-life supports once-daily oral dosing
Expert Statements
Anuj Gaggar, Chief Medical Officer of Assembly Bio
“Advancing ABI-6250 into Phase 2 represents an important milestone in our efforts to provide people living with chronic HDV infection a convenient, once-daily oral alternative to the currently available daily injectable therapy.”
Anuj Gaggar, Chief Medical Officer of Assembly Bio
“Supported by encouraging Phase 1a findings, this study will help evaluate the potential of ABI-6250 to deliver meaningful antiviral activity through a differentiated treatment approach.”
– Phase 2 study will evaluate the safety, pharmacokinetics and antiviral activity of ABI-6250 in participants with chronic HDV infection – – Initial data from the Phase 2 study is expected in the fourth quarter of 2027 –
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced dosing of the first two participants in a Phase 2 clinical study of ABI-6250, the company’s investigational oral small-molecule entry inhibitor candidate, in participants with chronic hepatitis delta virus (HDV) infection.
Get started
Create a free account to read the full story.